Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adverse Event Codes From IMDRF Now Used By FDA’s eMDR System

Executive Summary

The US FDA has updated its electronic Medical Device Reporting system to accept adverse event codes devised by the International Medical Device Regulators Forum. The agency is urging reporters using an AS2 submission account to “update their systems as soon as possible.”

You may also be interested in...



FDA Releases Plan For Enhancing eMDR Adverse Event Reporting System

The US agency has announced some changes it plans to make to its electronic Medical Device Reporting system over the coming year.

FDA Tweaks 3500A Form For Reporting Adverse Events, Plans September Changes To eMDR System

An update by the US agency to its MedWatch 3500A adverse event reporting form targets summarized events and patient gender. The FDA is also updating its electronic Medical Device Reporting (eMDR) system to accommodate the changes made to the 3500A, among other revisions.

Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot

In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT143684

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel